HEALTHEQUITY Earnings Preview: Recent $HQY Insider Trading, Hedge Fund Activity, and More

HealthEquity ($HQY) is scheduled to release quarterly earnings on June 3rd, with analysts anticipating revenues of $325.88 million and EPS of $0.82. Recent insider trading activity shows a net selling trend, while Q1 2025 institutional investor activity was mixed, with some firms significantly increasing their positions (CIBC Private Wealth Group, Invesco, Morgan Stanley, Price T Rowe, and Westfield Capital Management) and others decreasing (Wealthfront Advisers, Millennium Management). Analyst ratings are generally positive, with Raymond James issuing a "Strong Buy" rating and a price target of $115.

Analysis

HealthEquity ($HQY) is scheduled to announce its quarterly financial results on Tuesday, June 3rd, post-market closure, with analysts forecasting revenues of $325.88 million and earnings per share (EPS) of $0.82. This earnings release will be closely watched, particularly in light of significant insider selling activity over the past six months, where insiders executed 12 sales and no purchases. Notable sales include those by Stuart B. Parker (25,000 shares for approximately $2.42 million) and Robert W Selander (19,750 shares for roughly $1.92 million). This pattern of insider dispositions, along with a minor sale by a member of Congress, contributes to a moderately negative sentiment score of -0.3 for the stock, signaling potential caution from those with intimate knowledge of the company.

Contrasting the insider activity, institutional holdings in Q1 2025 presented a mixed scenario: 267 institutions increased their positions while 231 decreased theirs. A substantial divestment was observed from Wealthfront Advisers LLC, which liquidated its entire holding of over 107 million shares (valued at approximately $9.49 billion), and Millennium Management LLC reduced its stake by 60.8% (around $80.66 million). Conversely, significant capital flowed in from other institutions, including CIBC Private Wealth Group (adding 914,461 shares, an increase of 1432.1%), Invesco LTD. (adding 821,425 shares, +50.6%), and Price T Rowe Associates (adding 580,988 shares, +995.6%). HealthEquity also received $18.74 million in government contract award payments over the last year, indicating a source of stable revenue. Despite the insider sales and mixed institutional picture, Wall Street analyst sentiment remains positive, with two recent buy ratings (Raymond James: "Strong Buy"; JMP Securities: "Outperform") and no sell ratings. The median analyst price target stands at $113.5, with Raymond James setting a target of $115.

Key Decisions for Investors

• Investors should closely monitor HealthEquity's upcoming June 3rd earnings release, particularly its performance against the $325.88 million revenue and $0.82 EPS expectations, as this will be a key near-term catalyst.
• The consistent and exclusively negative insider trading activity over the past six months warrants caution; scrutinize management's commentary during the earnings call for any explanations regarding these sales.
• Consider the divergent signals from the significant Wealthfront Advisers exit versus new substantial institutional investments and positive analyst price targets (median $113.5) in the context of the upcoming earnings report before making significant portfolio adjustments.